OLA: Tear-Based AI-Driven Molecular Screening for Early Cancer Detection

OLA is a breakthrough point-of-care diagnostic platform that revolutionizes early cancer screening. By utilizing a disposable, microfluidic COC bio-chip, the system analyzes a single drop of tear fluid to detect cancer-associated biomarkers. Integrated with deep learning, OLA provides rapid, non-invasive, and clinical-grade diagnostic insights, empowering early intervention for breast and lung cancer.